Cargando…
Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles
OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation...
Autores principales: | Shiozaki, Afonso A., Senra, Tiago, Morikawa, Aleksandra T., Deus, Débora F., Paladino, Antonio T, Pinto, Ibraim M.F., Maranhão, Raul C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975788/ https://www.ncbi.nlm.nih.gov/pubmed/27626473 http://dx.doi.org/10.6061/clinics/2016(08)05 |
Ejemplares similares
-
Evaluation of atherosclerotic lesions in cholesterol-fed mice during treatment with paclitaxel in lipid nanoparticles: a magnetic resonance imaging study
por: Lima, Aline D., et al.
Publicado: (2017) -
Use of paclitaxel carried in solid lipid nanoparticles to prevent peritoneal fibrosis in rats
por: Silva, Filipe M. O., et al.
Publicado: (2022) -
Organic effects of associating paclitaxel with a lipid-based nanoparticle system on a nonhuman primate, Cebus apella
por: Feio, Danielle Cristinne Azevedo, et al.
Publicado: (2017) -
Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice
por: Kretzer, Iara F, et al.
Publicado: (2016) -
Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits
por: Vital, Carolina G., et al.
Publicado: (2022)